An energy utilization system and a method for manufacturing a carbon-containing material are provided that make it possible to obtain a carbon-containing material while suppressing release of carbon dioxide and reducing carbon dioxide. An energy utilization system (1) comprises: a heat utilization cycle (30) that has a high-temperature-utilizing heat exchange unit (36) for adjusting the temperature of a heat medium by utilizing energy obtained from renewable energy or waste heat, the heat utilization cycle (30) having a heat medium circulating therein; and an electrolytic reduction device (70) for electrolytically reducing an electrolytic solution in which carbon dioxide is dissolved. The electrolytic reduction device (70) electrolytically reduces the electrolytic solution of which the temperature has been adjusted by being in thermal contact with the heat medium. The electrolytic reduction device (70) includes: a cylindrical electrolytic cell casing (79) extending in a first direction; an anode (71) provided inside the electrolytic cell casing (79) and extending in the first direction; a cylindrical cathode (72) which is positioned inside the electrolytic cell casing (79) and outside the anode (71) when viewed in the first direction, and which extends in the first direction; and an electrolytic solution flow path (73) for allowing the electrolytic solution to flow in the first direction between the anode (71) and the cathode (72).
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
Provided are a detoxifying agent and detoxifying agent kit for simultaneous detoxification of CO and HCN in the body. The detoxifying agent for removal of carbon monoxide and hydrogen cyanide in the body includes as active ingredients a first inclusion complex wherein a first cyclodextrin dimer represented by general formula (1) below clathrates a first water-soluble metal porphyrin in which the central metal is divalent, and a second inclusion complex wherein a second cyclodextrin dimer represented by general formula (2) below clathrates the first water-soluble metal porphyrin in which the central metal is divalent, and further includes a reducing agent if necessary.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method for producing a metal carbide, the method including: an electrode production step in which a first molten salt containing carbonate ions and at least one kind of first metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions is prepared, and a second electrode is obtained by applying a voltage to the first molten salt so as to have a precipitate containing carbon precipitated on a first electrode; and an electrolysis step in which a voltage is applied to a second molten salt containing at least one kind of second metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions using the second electrode so as to obtain a carbide composition that contains a carbide of the second metal.
C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
This method for producing metal carbide comprises: preparing a molten salt containing at least one type of first metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions; readying an electrode containing carbon; and applying a voltage to the molten salt using the electrode to obtain a metal carbide composition containing carbide of the first metal.
C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
A method for producing a hydrocarbon, including: preparing a molten salt containing an oxide of a first metal; adding carbon dioxide to the molten salt; obtaining precipitates containing a first metal carbide by applying a voltage to the molten salt containing carbon dioxide; and obtaining a gas containing a hydrocarbon and a hydroxide of the first metal by hydrolyzing the first metal carbide.
C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
C01B 32/935 - Carbides of alkali metals, strontium, barium or magnesium
A method for producing a hydrocarbon including: preparing a molten salt containing a carbonate of a first metal; obtaining precipitates containing a first metal carbide by applying a voltage to the molten salt; and obtaining a gas containing the hydrocarbon and a hydroxide of the first metal by hydrolyzing the first metal carbide.
An energy utilization system includes a circulation circuit. The circulation circuit includes a pump, a heating section, an electrolytic reduction apparatus, and a thermal energy recovery section. The pump receives a heating medium and outputs the heating medium. The heating section heats the heating medium by using renewable energy or energy obtained from waste heat. The electrolytic reduction apparatus heats an electrolytic solution with heat from the heating medium. The circulation circuit circulates the heating medium. A method for producing a carbon-containing material includes heating a heating medium circulating in a circulation circuit by using renewable energy or energy obtained from waste heat, and performing electrolytic reduction by heating an electrolytic solution with heat from the heating medium that has been heated.
Realized are a carbon support for a fuel cell catalyst and a catalyst for a fuel cell which have excellent durability and excellent catalytic activity when a catalyst metal is supported. A carbon support according to an embodiment of the present invention has diffraction peaks of a (002) plane which are observed at least at 2θ=22.5° to 25°, 26°, and 26.5° in an X-ray diffraction spectrum with CuKα rays, has an intensity ratio I(P1)/I(P2) between a peak P1 at 2θ=26° and a peak P2 at 2θ=26.5° of not less than 1.4, and has a BET specific surface area of not less than 1000 m2/g.
An ultrasonic light deflector 1 provided with an ultrasound emission unit 2 for emitting ultrasound and a transparent material part 3 through which ultrasound propagates and through which light is transmitted, the ultrasonic light deflector 1 characterized in that the ultrasound emission unit 2 emits ultrasound towards a light beam L in the transparent material part 3 so that the direction of travel of the ultrasound and the direction of travel of the light beam L in the transparent material part 3 intersect, and the transparent material part 3 produces a static refractive index change and causes the light beam L to deflect while the ultrasound is being emitted.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
An SPR ultrasonic sensor 110 comprises a prism 111 that allows a laser beam to pass therethrough and a metallic membrane 112 that reflects a laser beam. In the ultrasonic sensor, surface plasmon resonance is generated when a laser beam is incident on the metallic membrane 112, and the resonance angle is shifted when the metallic membrane 112 is irradiated with an ultrasonic wave. The ultrasonic sensor is characterized in that the metallic membrane 112 is formed only on a portion of a first surface 111A such that the area of a laser-beam irradiation spot formed on said surface 111A includes a metallic area and a non-metallic area.
The present invention provides a method for manufacturing diamond, comprising electrolytically reducing carbon dioxide into diamond to obtain diamond in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide, wherein the electrolytic solution comprises an ionic liquid.
Provided is a novel compound having self-assembly activity. The compound is a compound represented by chemical formula (1), a tautomer or stereoisomer thereof, or a salt of these. In chemical formula (I), R122-R11, R11is a hydrogen atom or a discretionary substituent, R2and R3are each a hydrogen atom, a halogen, a nitro group, a straight-chain or branched alkyl group, a straight-chain or branched alkoxy group, or a cyano group, one or more hydrogen atoms of the alkyl group or the alkoxy group may additionally be substituted or not substituted with a substituent, or R2and R3 may be integrated and form a cyclic structure together with the benzene ring to which these moieties are bonded, each instance of X is a hydrogen atom or a discretionary substituent, the individual instances of X may be the same or different, and Z is a hydrogen atom or a discretionary substituent.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
14.
GOLD-SUPPORTED CARBON CATALYST AND METHOD FOR MANUFACTURING SAME
A gold-supported carbon catalyst includes gold fine particles supported on carbon black, wherein the gold fine particles are coordinated by an alkanethiol at a coverage of from 10% to 70%, and wherein the gold fine particles have an average particle diameter of from 1.0 nm to 1.5 nm.
An electrode used for oxygen reactions, the electrode being excellent in catalytic activity and stability, a method of producing the electrode, and an electrochemical device using the electrode are provided. This electrode includes, as an oxygen catalyst, an oxide that has peaks at positions of 2θ=34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuKα ray and has constituent elements of bismuth, ruthenium, sodium, and oxygen.
[Problem] One purpose of the present invention is to provide a vapor generation material which enables the achievement of a vapor of a vaporizable substance stably with high efficiency, while suppressing outgas and splash. Another purpose of the present invention is to provide a vapor generation material which enables a vaporizable substance to be vaporized at low temperatures. Another purpose of the present invention is to provide a vapor generation material which is in a solid state and has improved transportability and handleability. [Solution] In order to achieve the above, a vapor generation material according to the present invention generates a vapor by mean of heating, and is characterized by comprising at least one material that is a vaporizable substance, and a supporting material.
C23C 16/448 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for generating reactive gas streams, e.g. by evaporation or sublimation of precursor materials
17.
METHOD FOR MANUFACTURING CARBON MONOXIDE OR ORGANIC COMPOUND
A method for manufacturing carbon monoxide or an organic compound, which includes electrolytically reducing carbon dioxide to obtain carbon monoxide or an organic compound in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide. Carbon dioxide is selectively reduced into carbon monoxide or a specific organic compound by a potential to be applied to between the anode and the cathode.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
THE DOSHISHA (Japan)
SENJU PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abstract
The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
19.
CORNEAL ENDOTHELIAL CELL PREPARATION CONTAINING NO CULTURE-DERIVED COMPONENT, AND METHOD FOR PRODUCING SAME
The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial cell preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin and combinations thereof.
Provided are an energy usage system with which it is possible to reduce carbon dioxide and obtain a carbon-containing material while suppressing release of carbon dioxide, and a method for manufacturing a carbon-containing material. The energy usage system (201) is provided with a circulation circuit (230) through which water circulates, the circulation circuit (230) having a pump (232) for intaking and pumping water, a waste heat boiler (236) for heating the water using energy obtained by waste heat, an electrolytic reduction device (70) for heating an electrolytic solution using the heat of the water, and a generator (20).
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.
In a case where an alkali aqueous solution is used as an electrolyte, provided are an oxygen catalyst excellent in catalytic activity and composition stability, an electrode having high activity and stability using this oxygen catalyst, and an electrochemical measurement method that can evaluate the catalytic activity of the oxygen catalyst alone. The oxygen catalyst is an oxide having peaks at positions of 2θ=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuKα ray, and having constituent elements of bismuth, ruthenium, sodium, and oxygen. An atom ratio O/Bi of oxygen to bismuth and an atom ratio O/Ru of oxygen to ruthenium are both more than 3.5.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
H01M 12/04 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type
23.
CARBON CARRIER FOR FUEL CELL CATALYST AND FUEL CELL CATALYST
Realized are a carbon support for a fuel cell catalyst and a catalyst for a fuel cell which have excellent durability and excellent catalytic activity when a catalyst metal is supported. A carbon support according to an embodiment of the present invention has diffraction peaks of a (002) plane which are observed at least at 2? = 22.5° to 25°, 26°, and 26.5° in an X-ray diffraction spectrum with CuK? rays, has an intensity ratio I(P1)/I(P2) between a peak P1 at 2? = 26° and a peak P2 at 2? = 26.5° of not less than 1.4, and has a BET specific surface area of not less than 1000 m2/g.
The present invention realizes a carbon carrier for a fuel cell catalyst and a fuel cell catalyst, having excellent durability and catalytic activity when carrying a catalyst metal. A carbon carrier according to one embodiment of the present invention is such that, in the X-ray diffraction spectrum using CuKα rays, diffraction peaks of a (002) plane are observed at at least 2θ = 22.5° to 25°, 26°, and 26.5°, the intensity ratio I(P1)/I(P2) of a peak P1 at 2θ = 26° to a peak P2 at 2θ = 26.5° is 1.4 or more, and the BET specific surface area is 1000 m2/g or more.
The present disclosure provides a method for cryopreserving corneal endothelial cells and/or corneal-endothelial-like cells, and a freezing preparation for corneal endothelial cells and/or corneal-endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal-endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and/or corneal-endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C/min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and/or corneal-endothelial-like cells in a frozen state.
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
The present disclosure provides a method for cryopreserving corneal endothelial cells and/or corneal-endothelial-like cells, and a freezing preparation for corneal endothelial cells and/or corneal-endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal-endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and/or corneal-endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C/min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and/or corneal-endothelial-like cells in a frozen state.
The present invention addresses the problem of providing a detoxifying agent and a detoxifying agent kit both for detoxifying CO and HCN in a living body simultaneously. Provided is a detoxifying agent for removing carbon monoxide and hydrogen cyanide from a body, the detoxifying agent being characterized by containing, as active ingredients, a first inclusion complex having such a structure that a first cyclodextrin dimer represented by general formula (1) includes a first water-soluble metal porphyrin having a bivalent central metal and a second inclusion complex having such a structure that a second cyclodextrin dimer represented by general formula (2) includes a first water-soluble metal porphyrin having a bivalent central metal, and also characterized by further containing a reducing agent if necessary (In formulae (1) and (2), R represents a protective group protecting a hydroxyl group of the cyclodextrin, m and p each represent an integer of 1 or 2, and n and q each represent an integer of 1-3.).
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
This anode structure (10) for a secondary battery has a main portion (12) in the form of a foil or a thin plate containing zinc as a base material, and an non-electron-conductive film (11) located on at least one surface of the main portion (12). The film (11) has elastic properties. The film (11) is provided with an opening (13) formed such that a part of a surface of the main portion (12) is exposed, and an electrode reaction inhibiting portion (14) that surrounds the opening (13) and inhibits an electrode reaction of the main portion (12). The film (11) is bonded to the main portion (12) in a liquid-tight manner.
H01M 50/474 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their position inside the cells
H01M 50/477 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their shape
H01M 50/48 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by the material
30.
METHOD FOR PRODUCING METAL CARBIDE, METHOD FOR PRODUCING HYDROCARBON, AND METAL CARBIDE COMPOSITION
Provided are: a method for producing a metal carbide using carbon dioxide as a carbon source and a metal oxide as a metal source; a method for producing a hydrocarbon from the metal carbide obtained using carbon dioxide as a carbon source and a metal oxide as a metal source; and a metal carbide composition. This method for producing a metal carbide includes: preparing a molten salt containing a first metal oxide; adding carbon dioxide to the molten salt; applying voltage to the molten salt containing the carbon dioxide; and obtaining a precipitate containing a carbide of the first metal. Furthermore, this method for producing a hydrocarbon includes hydrolyzing a carbide of the first metal so as to obtain a hydrocarbon-containing gas and a hydroxide of the first metal.
C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
Provided are a method for producing a metal carbide using a metal carbonate as a metal source, a method for producing a hydrocarbon from a metal carbide obtained using a metal carbonate as a metal source, and a metal carbide composition. Provided is a method for producing a metal carbide, the method including preparing a molten salt including a carbonate of a first metal, and applying a voltage to the molten salt to obtain a precipitate including a carbide of the first metal. Also provided is a method for producing a hydrocarbon, the method including hydrolyzing the carbide of a first metal to obtain a hydrocarbon and a hydroxide of the first metal.
C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
There are provided a method for predicting a springback amount and a method for bending a deformed reinforcing bar including: supplying the deformed reinforcing bar bending the supplied deformed reinforcing bar, and subsequently measuring a first bending angle in a state of releasing a bending force on the deformed reinforcing bar; further bending the reinforcing bar from which the bending force has been released, and subsequently measuring a second bending angle in a state of releasing the bending force; and predicting a relationship between the bending angle and the springback amount by using the measurement results after executing the further bending once or a plurality of times, in which the bending angle is greater for subsequent steps.
H04B 7/08 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the receiving station
34.
MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOF
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
35.
Liquid Flow Formation Method and Object Moving Method Using Same
The present disclosure provides a method for forming a liquid flow in a surface region of a liquid, and a method for moving a larger object in a non-contact and non-invasive manner.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
B82Y 40/00 - Manufacture or treatment of nanostructures
36.
Receiver apparatus, and method for producing parameters for demodulation
A method implemented in a computer system includes training a network, which is obtained by unfolding an iterative algorithm for demodulation or demodulation and decoding, using a machine learning technique with a loss function that takes into account non-Gaussianity of a log-likelihood ratio (LLR) distribution calculated from an output of the network. The method further includes producing a first set of learned parameters of that iterative algorithm.
Provided is a metal negative electrode used for a secondary battery. The metal negative electrode includes an active material portion, a current collector, and a non-electronically conductive reaction space divider. The active material portion forms metal during charging and forms an oxidation product of the metal during discharging. The metal is used as a negative-electrode active material. The current collector is electrically connected to the active material portion. The non-electronically conductive reaction space divider is integrally formed with or connected to the current collector and/or the active material portion. The reaction space divider has a plurality of electrolyte holder portions configured to hold a liquid electrolyte.
Kyoto Prefectural Public University Corporation (Japan)
The Doshisha (Japan)
Senju Pharmaceutical Co., Ltd. (Japan)
Inventor
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abstract
The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
The present disclosure provides a method for producing a carbon material, wherein a carbon material is obtained by electrolytically reducing carbon dioxide in an electrolytic reduction apparatus that comprises an anode electrode, a cathode electrode and an electrolyte solution that contains carbon dioxide. With respect to this method for producing a carbon material, the electrolyte solution contains an ionic liquid.
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material
The present invention provides a method for manufacturing carbon monoxide or an organic compound in which carbon dioxide is electrolytically reduced and carbon monoxide or the organic compound is obtained in an electrolytic reduction device having an anode electrode, a cathode electrode, and an electrolytic solution containing carbon dioxide, wherein said method for manufacturing carbon monoxide or an organic compound comprises the electrolytic solution containing an ionic liquid and water.
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material
C25B 11/042 - Electrodes formed of a single material
A varifocal gel lens 1 comprising an annular ultrasonic transducer 3, a transparent and elastic lens 4, and a drive unit 5 that applies an electric signal to the ultrasonic transducer 3 to generate an ultrasonic wave is characterized in that the ultrasonic transducer 3 includes four electrodes 31 to 34 divided into N in the circumferential direction, and the drive unit 5 has a traveling wave mode in which electric signals of different phases that increase or decrease in the circumferential direction are applied to the four electrodes 31 to 34 and an ultrasonic wave propagating in the circumferential direction of the lens 4 is generated to raise a peripheral portion of the lens 4.
[Problem] To provide a gold-supported carbon catalyst in which the size of gold fine particles is reduced and the strength of adhesion thereof to carbon black is increased, and aggregation of gold fine particles can be suppressed. [Solution] A gold-supported carbon catalyst in which alkanethiol is coordinated with a coverage factor of 10-70%, and gold fine particles having an average particle diameter of 1.0-1.5 nm are supported on carbon black.
B22F 9/00 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
The present invention provides: an electrode which is used for oxygen reactions and which is excellent in catalyst activity and stability; a method for preparing the electrode; and an electrochemical device using the electrode. This electrode is provided with an oxide, as an oxygen catalyst, which has peaks at positions of 2? = 30.07° ± 1.00°, 34.88° ± 1.00°, 50.20° ± 1.00° and 59.65° ± 1.00° in X-ray diffraction measurements using CuK? rays and which contains, as constituent elements, bismuth, ruthenium, sodium and oxygen.
C25B 11/073 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material
H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
44.
ELECTRODE, METHOD FOR PREPARING SAID ELECTRODE, AND ELECTROCHEMICAL DEVICE USING SAID ELECTRODE
The present invention provides: an electrode which is used for oxygen reactions and which is excellent in catalyst activity and stability; a method for preparing the electrode; and an electrochemical device using the electrode. This electrode is provided with an oxide, as an oxygen catalyst, which has peaks at positions of 2θ = 30.07° ± 1.00°, 34.88° ± 1.00°, 50.20° ± 1.00° and 59.65° ± 1.00° in X-ray diffraction measurements using CuKα rays and which contains, as constituent elements, bismuth, ruthenium, sodium and oxygen.
H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
C25B 11/073 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
45.
OXYGEN CATALYST AND ELECTRODE USING SAID OXYGEN CATALYST
Provided are: an oxygen catalyst that uses an alkaline aqueous solution as an electrolyte and has high catalytic activity; and an electrode. The oxygen catalyst according to the present invention is an oxygen catalyst in which an alkaline aqueous solution is used as an electrolyte, the oxygen catalyst being characterized by having a pyrochlore oxide structure including bismuth on an A-site and ruthenium on a B-site, and containing manganese as well as bismuth and ruthenium. The electrode according to the present invention is characterized by using the oxygen catalyst according to the present invention.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
46.
METHOD FOR ENHANCING THERAPEUTIC EFFECT OF CORNEAL ENDOTHELIAL CELL INJECTION THERAPY
The present disclosure provides a composition for enhancing the therapeutic effect of cell injection therapy, said therapy aiming at treating or preventing a corneal endothelial symptom, disorder or disease. In one embodiment, the present disclosure provides a composition, which comprises a ROCK inhibitor, for enhancing the therapeutic effect of cell injection therapy, said therapy aiming at treating or preventing a corneal endothelial symptom, disorder or disease of a subject. This composition, which is to be used in combination with corneal endothelial cells and/or corneal endothelial-like cells, is characterized in that the composition is administered prior to the injection of the corneal endothelial cells and/or corneal endothelial-like cells into the anterior chamber of the subject. In some embodiments, the composition, etc. of the present disclosure are formulated into eye-drops.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
The present disclosure provides a method for preserving corneal endothelial cells. The present disclosure provides a method for preserving a suspension of corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells accommodated in a vessel while shaking the same for at least a certain time. In some embodiments, shaking may be reciprocal shaking, giratory shaking, horizontal eccentric shaking, wave-shape (seesaw) shaking, figure-of-eight shaking, or rotary shaking.
1355 (third period) continuously passed in which variation was less than or equal to a threshold value γ (third threshold value). If data extraction parameters including each of these determinations are satisfied, the data extraction unit 23 extracts data regarding this transient reponse time from a storage unit 22.
A S100A8-inhibiting peptide comprises (A) a peptide which comprises a portion of the amino acid sequence represented by SEQ ID NO: 1, contains an alanine (Ala) residue located at position-5 from the N-terminal of the aforementioned amino acid sequence, and has a length composed of 5 to 10 residues or (B) a peptide which comprises the amino acid sequence represented by SEQ ID NO: 2.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Provided are: an oxygen catalyst having excellent catalytic activity and composition stability in the case of using an alkaline aqueous solution as an electrolyte; an electrode having high activity and stability using said oxygen catalyst; and an electrochemical measurement method that can evaluate the catalytic activity of an oxygen catalyst alone. The oxygen catalyst is an oxide that has peaks at the positions of 2θ=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in X-ray diffraction measurements using CuKα-rays and that contains, as constituent elements, bismuth, ruthenium, sodium, and oxygen, wherein both the atomic ratio O/Bi of oxygen to bismuth and the atomic ratio O/Ru of oxygen to ruthenium are greater than 3.5.
H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
A computer system includes at least one memory and at least one processor coupled to the at least one memory and configured to execute one or more sets of instructions. The one or more sets of instructions, when executed by the at least one processor, cause the computer system to provide virtualized radio access network functions including executing a BP algorithm and provide controller functions including adjusting the total number of iterations of the BP algorithm depending on available computing resources of the computer system.
A BP detector of a wireless receiver apparatus reads a first parameter set or a second parameter set. The first parameter set includes a plurality of scaling factors and a plurality of damping factors learned together using a deep learning technique. The second parameter set includes a plurality of scaling factors and a plurality of node selection factors learned together using a deep learning technique from a memory. The BP detector executes an iterative BP algorithm that uses the first parameter set or the second parameter set in order to perform multi-user detection.
H04L 1/00 - Arrangements for detecting or preventing errors in the information received
H03M 13/11 - Error detection or forward error correction by redundancy in data representation, i.e. code words containing more digits than the source words using block codes, i.e. a predetermined number of check bits joined to a predetermined number of information bits using multiple parity bits
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
54.
ZINC NEGATIVE ELECTRODE AND MANUFACTURING METHOD THEREFOR, AND SECONDARY CELL COMPRISING SAID ZINC NEGATIVE ELECTRODE AND MANUFACTURING METHOD THEREFOR
Provided are: a zinc negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a manufacturing method therefor; a secondary cell using the zinc negative electrode; and a manufacturing method therefor. A zinc negative electrode used in a secondary cell, wherein the zinc negative electrode comprises: an active material part in which zinc is generated during charging, and oxidized zinc is generated during discharging, the zinc being used as a negative electrode active material; a collector that is electrically connected to the active material part; and a non-electron-conductive reaction space restriction part that is integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts comprising a space that can hold a liquid electrolyte.
Proposed are a carbon monoxide quantification method and a carbon monoxide measurement kit, whereby it becomes possible to measure a trace amount of carbon monoxide contained in blood or a tissue with high accuracy in a simple manner without the need to use a carbon monoxide gas that is harmful to the human body. A method for quantifying carbon monoxide contained in a sample, the method comprising the steps of: using the sample and an inclusion complex for quantification use in which a cyclodextrin dimer includes a water-soluble metal porphyrin to prepare an aqueous inclusion complex solution containing, as substances derived from the inclusion complex for quantification use, only a deoxy inclusion complex (II) which has a bivalent center metal and is not bonded to oxygen or carbon monoxide and a CO-bonded inclusion complex (II) which is produced as the result of the bonding of the deoxy inclusion complex (II) with carbon monoxide in the sample; measuring an ultraviolet-visible absorption spectrum of the inclusion complex solution; and calculating the quantity of carbon monoxide in the sample in accordance with a formula established based on the Lambert–Beer law employing each of a first inflection point observed at a wavelength of around 422 nm and a second inflection point observed at a wavelength of around 434 nm in the ultraviolet-visible absorption spectrum obtained by the above-mentioned measurement.
G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
G01N 33/483 - Physical analysis of biological material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
56.
Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof
Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
2. Accordingly to the present invention, corneal endothelial cells can be preserved at a high cell survival rate. Corneal endothelial cells preserved in this manner have functions of normal corneal endothelial cells. Such cells can also be used as cells for treating a corneal endothelial disease or the like.
Provided is a method for efficiently producing an epoxy compound using an electrochemical method. This method for producing an epoxy compound comprises electrically oxidizing a salt represented by formula (a) in an aqueous phase to yield a peracid ion represented by formula (b) and oxidizing an olefin with the yielded peracid ion represented by formula (b) to obtain a corresponding epoxy compound. In the formulae, Rd22, CO, and P(=O)OH and A+ represents a cation selected from among alkali metal, alkaline-earth metal, ammonium, phosphonium, and sulfonium ions.
C07D 301/12 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with hydrogen peroxide or inorganic peroxides or peracids
Provided is a method for moving a larger object in a contactless and non-invasive manner. In this method for forming a liquid flow at a surface region of a liquid, a laser beam (14) is emitted onto a specific surface region (18) of a dispersed microparticle-containing liquid (10) in which an object floats, thereby causing the temperature of the specific surface region of the liquid to be relatively higher than another neighboring surface region so as to form a temperature gradient between the two surface regions of the liquid.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
B82Y 40/00 - Manufacture or treatment of nanostructures
60.
METAL NEGATIVE ELECTRODE, METHOD FOR FABRICATING THE SAME AND SECONDARY BATTERY INCLUDING THE SAME
Provided are: a metal negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a method for manufacturing same; and a secondary cell in which the metal negative electrode is used. A metal negative electrode used in a secondary cell, wherein the metal negative electrode comprises: an active material part in which a metal is produced during charging and an oxidation product of the metal is produced during discharging, the metal being used as a negative electrode active material; a collector electrically connected to the active material part; and a non-electron-conductive reaction space restriction part integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts capable of holding a liquid electrolyte.
H01M 50/477 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their shape
H01M 50/474 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their position inside the cells
Provided are: a metal negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a method for manufacturing same; and a secondary cell in which the metal negative electrode is used. A metal negative electrode used in a secondary cell, wherein the metal negative electrode comprises: an active material part in which a metal is produced during charging and an oxidation product of the metal is produced during discharging, the metal being used as a negative electrode active material; a collector electrically connected to the active material part; and a non-electron-conductive reaction space restriction part integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts capable of holding a liquid electrolyte.
Kyoto Prefectural Public University Corporation (Japan)
The Doshisha (Japan)
Inventor
Ikeda, Hanako
Kakizuka, Akira
Kinoshita, Shigeru
Nakamura, Takahiro
Nagata, Maho
Koizumi, Noriko
Okumura, Naoki
Abstract
The inventors have found that VCP inhibitors protect corneal endothelial cells and corneal epithelial cells. Accordingly, the disclosure provides a composition for protecting a cornea comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. In another aspect the disclosure provides a composition for treating and/or preventing a corneal disease comprising a compound of formula (I). In a further aspect the disclosure provides a composition for ocular irrigation comprising a compound of formula (I). In a still further aspect the disclosure provides a composition for preserving a corneal graft comprising a compound of formula (I).
Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-β (TGF-β) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-β signal is Fuchs' corneal endothelial dystrophy.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
64.
Resin composition and method for determining flame retardancy of resin composition
C04B 35/563 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides based on boron carbide
C04B 35/58 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides
Provided is a novel compound capable of efficiently introducing CO into cells. The novel compound is represented by formula (A). In the formula, R represents hydrogen or an alkyl group which has 1-8 carbon atoms and optionally has a substituent such as a halogen atom or an aryl group.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic Table
One aspect of the present invention is a nonaqueous electrolyte for an energy storage device comprising: an alkali metal salt; a first aprotic organic solvent coordinating to an alkali metal ion in the alkali metal salt, and not including a fluorine atom; a second aprotic organic solvent including a fluorine atom; and an additive comprising a polar group and a group including a fluorine atom, wherein a content of the alkali metal salt is no less than 0.9 mol/kg and less than 2 mol/kg, a content of the first aprotic organic solvent with respect to the content of the alkali metal salt in terms of a molar ratio is no less than 0.7 and no greater than 4, and a content of the second aprotic organic solvent with respect to a total amount of the first aprotic organic solvent, the second aprotic organic solvent and the additive is no less than 40% by volume.
H01M 10/0569 - Liquid materials characterised by the solvents
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/0567 - Liquid materials characterised by the additives
H01M 4/02 - Electrodes composed of, or comprising, active material
68.
HYDROPHILIC POLYMER CROSSLINKED NETWORK HYDROGEL AND ACTIVE OXYGEN INHIBITOR
Provided is a novel hydrophilic polymer crosslinked network hydrogel. Also provided is an active oxygen inhibitor that senses ROS in a place where an excessive amount of ROS are present and releases an antioxidant. The hydrophilic polymer crosslinked network hydrogel comprises manganese tetrakis(4-carboxyphenyl)porphyrin and a linker L, said linker L having a polyethylene glycol chain linking manganese tetrakis(4-carboxyphenyl)porphyrin molecules to each other, and holds manganese tetrakis(4-carboxyphenyl)porphyrin within a network.
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61P 39/06 - Free radical scavengers or antioxidants
C08G 65/337 - Polymers modified by chemical after-treatment with organic compounds containing other elements
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Provided are: an oxygen catalyst that uses an alkaline aqueous solution as an electrolyte and has high catalytic activity; and an electrode. The oxygen catalyst according to the present invention is an oxygen catalyst in which an alkaline aqueous solution is used as an electrolyte, the oxygen catalyst being characterized by having a pyrochlore oxide structure including bismuth on an A-site and ruthenium on a B-site, and containing manganese as well as bismuth and ruthenium. The electrode according to the present invention is characterized by using the oxygen catalyst according to the present invention.
PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY (Japan)
Inventor
Akiyama, Iwaki
Tsujimoto, Yukako
Tanaka, Toshihiro
Hirai, Toshiko
Minamiguchi, Kiyoyuki
Abstract
An ultrasound diagnostic device 100 determines the effects of cancer treatment on a specific site of a subject on the basis of ultrasonic echo signals reflected by the subject. The ultrasound diagnostic device 100 is provided with: a first probe 11 which emits ultrasonic waves to the subject and receives an echo signal; an operation unit 8 for receiving a selection operation for the position of a specific site from a user; a second probe 12 which emits ultrasonic waves to warm the specific site; and a control unit 5 which acquires thermal property information for the specific site on the basis of an echo signal acquired before warming the specific site with the ultrasonic waves emitted from the second probe and an echo signal acquired after warming, and determines the presence or absence of a contrast agent at the specific site on the basis of the thermal property information.
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
72.
METHOD AND VESSEL FOR PRESERVING CORNEAL ENDOTHELIAL CELLS
The present disclosure provides a method for preserving corneal endothelial cells with a high cell survival rate. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells in a vessel that has a bottom surface area of at least about 0.7 cm2. According to the present invention, corneal endothelial cells can be preserved with a high cell survival rate. The corneal endothelial cells preserved in this manner have the functions of healthy corneal endothelial cells, and can be used as therapeutic cells such as for corneal endothelial disease.
An ion analyzer that generates product ions from precursor ions derived from a sample component and analyzes the product ions includes a reaction chamber (2) into which the precursor ion is introduced, a radical generation chamber (51), a material gas supply source (52) configured to introduce material gas into the radical generation chamber (51), a vacuum evacuator (57) configured to evacuate the radical generation chamber (51), a vacuum discharge unit (53) configured to generate a vacuum discharge in the radical generation chamber (51), a radical irradiation unit (54) configured to irradiate an inside of the reaction chamber (2) with radicals generated from the material gas in the radical generation chamber (51), and a separation and detection (3) configured to separate and detect product ions generated from the precursor ion by reaction with the radicals according to at least one of a mass-to-charge ratio and ion mobility.
H01J 49/00 - Particle spectrometers or separator tubes
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
The present disclosure provides a method for preserving corneal endothelial cells with a high cell survival rate. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells in a vessel that has a bottom surface area of at least about 0.7 cm2. According to the present invention, corneal endothelial cells can be preserved with a high cell survival rate. The corneal endothelial cells preserved in this manner have the functions of healthy corneal endothelial cells, and can be used as therapeutic cells such as for corneal endothelial disease.
The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides: a composition for preserving ocular cells, or culturing the same after preservation, the composition containing albumin and dimethyl sulfoxide; a cell preparation containing said ocular cells, albumin, and dimethyl sulfoxide; and a therapeutic/preventive method using the same. The present disclosure also provides a method for preserving corneal endothelial cells, the method including a step of suspending ocular cells in said composition to provide a suspension, and a step of freezing the suspension. In some embodiments, the ocular cells are corneal cells (for example, corneal endothelial cells).
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
Provided is a compound that specifically inhibits the production of Aβ protein and serves as an active component of a drug for treating and/or preventing Alzheimer's disease. The Aβ-protein-specific production inhibitor according to the present invention is characterized by containing a peptide (FGBTWDYWVYRRR, where B is an L-4,4'-biphenylalanine residue) that comprises an amino acid sequence set forth in SEQ ID NO: 1 and inhibits both β-secretase and γ-secretase activity. A peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 can be utilized in the prevention and/or treatment of Alzheimer's disease.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Multi-screw kneader and method for producing nano-composite using said multi-screw kneader, and disk-shaped segment used for said kneader and said method
A multi-screw kneader is configured to exhibit an extensional flow function before and behind holes of a disk-shaped segment and a method for producing a nano-composite uses the multi-screw kneader. The multi-screw kneader includes a plurality of kneading screws and the disk-shaped segment in a barrel. The disk-shaped segment partitions the inside of the barrel downstream of a part for supplying a kneading material and includes shaft receiving parts through which rotating shafts of the kneading screws are to rotatably pass and the holes are defined in a periphery of the shaft penetrating parts and are configured to serve as flow channels of the kneading material. The method for producing the nano-composite includes charging nanoparticles as a resin additive using the multi-screw kneader.
B29B 7/48 - MixingKneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
An analytical device includes: a reaction unit into which an ion derived from a sample component is introduced; a radical generation unit that generates a radical by vacuum discharge and comprises a raw material introduction chamber into which a plasma raw material is introduced; a connection part that introduces the radical generated in the radical generation unit into a vacuum chamber, the vacuum chamber having a pressure lower than a pressure of the raw material introduction chamber and being connected to the reaction unit; and a separation unit that separates a generated ion generated by a reaction with the radical introduced via the connection part into the reaction unit according to m/z and/or ion mobility, wherein an inner diameter of a cross section of the connection part is equal to or less than 20 millimeters.
H01J 49/06 - Electron- or ion-optical arrangements
H01J 49/26 - Mass spectrometers or separator tubes
81.
CYCLONE REFRIGERATION DEVICE, CYCLONE COOLNESS/HEAT RECOVERY UNIT, AND HEAT PUMP SYSTEM PROVIDED WITH SAID CYCLONE REFRIGERATION DEVICE OR CYCLONE COOLNESS/HEAT RECOVERY UNIT
The present invention is provided with a cylinder part 1, an exhaust pipe 3, a cooling part 4 having a cavity 4a that passes through an internal space 1b of the cylinder part, a refrigerant inflow pipe 5, and a decompression device 6. A liquid-phase refrigerant that has been condensed under high pressure is supplied to a refrigerant supply pipe and is decompressed by the decompression device to form a solid-gas two-phase refrigerant. The solid-gas two-phase refrigerant flows into the internal space of the cylinder part and forms a downward spiral, and is separated into a solid-phase refrigerant S and a gas-phase refrigerant. The solid-phase refrigerant S accumulates in the cavity, and the gas-phase refrigerant forms an upward spiral passing from a bottom part of the cavity through the interior space inside the downward spiral and flows out from the exhaust pipe. The present invention is also provided with: pipelines 7a, 7b through which a fluid to be cooled circulates, said pipelines 7a, 7b through which a fluid to be cooled circulates extending through the cavity of the cooling part, and a fluid to be cooled from a cooling load 9 is circulated through the interior of the pipelines through which a fluid to be cooled circulates; a heat exchanger 8 provided to a portion of the pipelines through which a fluid to be cooled circulates that is within the cavity, the heat exchanger 8 performing heat exchange between the solid-phase refrigerant S and the fluid to be cooled; and a pump 10 that circulates the fluid to be cooled.
F25B 1/00 - Compression machines, plants or systems with non-reversible cycle
F25B 7/00 - Compression machines, plants or systems, with cascade operation, i.e. with two or more circuits, the heat from the condenser of one circuit being absorbed by the evaporator of the next circuit
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
THE DOSHISHA (Japan)
Inventor
Ikeda, Hanako
Kakizuka, Akira
Kinoshita, Shigeru
Nakamura, Takahiro
Nagata, Maho
Koizumi, Noriko
Okumura, Naoki
Abstract
The inventors discovered that a certain type of VCP inhibitor has a protective effect on corneal endothelial cells and corneal epithelial cells. Consequently, a composition for corneal protection is provided which contains the compound of expression (I) or an ester, oxide, pharmaceutically permissible salt or solvate thereof. As another embodiment, a pharmaceutical composition is provided for the treatment and/or prevention of corneal disease that contains the aforementioned compound. As a further embodiment, a composition for ocular perfusion containing the compound is provided. As yet a further embodiment, a composition for transplanted cornea preservation containing said compound is provided.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
One embodiment of the present invention is a nonaqueous electrolyte for electricity storage elements, which contains an alkali metal salt, a first aprotic organic solvent that does not have a fluorine atom and is coordinated to an alkali metal ion which constitutes the alkali metal salt, a second aprotic organic solvent that has a fluorine atom, and an additive that has a polar group and a group having a fluorine atom. This nonaqueous electrolyte for electricity storage elements is configured such that: the content of the alkali metal salt is 0.9 mol/kg or more but less than 2 mol/kg; the content of the first aprotic organic solvent relative to the content of the alkali metal salt is from 0.7 to 4 (inclusive) in terms of the molar ratio; and the proportion of the content of the second aprotic organic solvent in the total content of the first aprotic organic solvent, the second aprotic organic solvent and the additive is 40% by volume or more.
H01M 10/0569 - Liquid materials characterised by the solvents
H01G 11/60 - Liquid electrolytes characterised by the solvent
H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
H01G 11/64 - Liquid electrolytes characterised by additives
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-.beta. (TGF-.beta.) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-.beta. signal is Fuchs' corneal endothelial dystrophy.
Provided is a drug or a method that uses a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative, to treat or prevent a corneal endothelial condition, disorder or disease caused by transforming growth factor beta (TGF-β) signalling in corneal endothelial cells. In a preferred embodiment, the corneal endothelial condition, disorder or disease caused by TGF-β signalling is Fuchs corneal endothelial dystrophy.
Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
89.
MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOF
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-.beta. (TGF-.beta.) signal and/or extracellular matrix (ECM).
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
The present invention provides a method for screening for a compound that is effective against disorders of the corneal endothelium. The method according to the present invention comprises: (a) a step for bringing candidate compounds into contact with immortalized cells of Fuchs' corneal endothelial dystrophy in the presence of transforming growth factor (TGF)-β, making evaluations on the inhibitory activity of said candidate compounds against said TGF-β, and selecting a compound having the inhibitory activity; (b) a step for evaluating the toxicity of the compound selected in step (a) with respect to said immortalized cells; (c) a step for evaluating the inhibitory activity of the compound selected in step (a) against said TGF-β; and (d) a step for selecting a compound that has been evaluated to have low toxicity to said immortalized cells in step (b) and has been evaluated to have inhibitory activity against said TGF-β in step (c). The method according to the present invention makes it possible to screen for a compound that is effective for disorders of the corneal endothelium.
COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT
The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF-β signaling in corneal endothelial cells. Provided by the present invention is a composition that includes a compound and that is for treating or preventing endothelial symptoms, disorders, or diseases, wherein, when the compound comes into contact with immortalized cells of Fuchs' corneal endothelial dystrophy, (i) said immortalized cells exhibit a cell survival rate (%) of approximately 90% or more after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S), and (ii) the ratio of caspase 3/7 activity (%) in the presence of TGF-β with respect to said cellular survival rate (%) is at most 0.8 after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S).
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
Provided is a method for producing a zinc oxide powder that exhibits an excellent antimicrobial performance even when blocked from light. This production method contains a step for adding 150-250 g of a hexagonal flake-shaped zinc oxide powder to 1 liter of an aqueous zinc nitrate solution having a concentration of 2-4 M (mol/L) and performing a hydrothermal treatment for 5-15 hours at 130°C-180°C, and a step for subjecting the basic zinc nitrate produced by this hydrothermal treatment to a heat treatment for 0.5-3 hours at a temperature of 550°C-700°C in air or an inert gas atmosphere. This heat treatment is preferably carried out at a temperature of 575°C-650°C, and the antimicrobial activity per unit mass can be increased by pulverizing the powder after the heat treatment.
Provided is an ion analyzer for generating product ions from specimen component-derived precursor ions, and analyzing such product ions, wherein the ion analyzer comprises: a reaction chamber (2) into which the precursor ions are introduced; a radical generation chamber (51); a source gas supply source (52) that introduces a source gas into the radical generation chamber (51); a vacuum exhaust unit (57) that exhausts the radical generation chamber (51); a vacuum discharge unit (53) that causes a vacuum discharge to be generated in the radical generation chamber (51); a radical irradiation unit (54) that irradiates inside the reaction chamber (2) the radicals generated from the source gas in the radical generation chamber (51); and a separation/detection unit (3) that separates and detects product ions generated from the precursor ions due to reaction with the radicals in accordance with the mass charge ratio and/or ion mobility.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
H01J 49/42 - Stability-of-path spectrometers, e.g. monopole, quadrupole, multipole, farvitrons
95.
RESIN COMPOSITION AND METHOD FOR DETERMINING FLAME RETARDANCY OF RESIN COMPOSITION
Provided are: a resin composition which is suitable for use in producing flame-retardant molded articles and which can impart high flame retardancy even when containing a flame retardant only in a small amount; and a flame retardancy determination method for determining the flame retardancy of a resin composition. The resin composition of the present invention comprises a thermoplastic resin, a cellulosic material, and a phosphoric-acid flame retardant and satisfies the following relationships (1) and (2). (In the relationships (1) and (2), TP, TB, and TCMP respectively indicate the following temperatures corresponding to peaks of weight loss rate in thermogravimetry: TP is the temperature (°C) at which the weight loss rate of the thermoplastic resin peaks, TB is the temperature (°C) at which the weight loss rate of the cellulosic material peaks, and TCMP is the temperature (°C) at which the weight loss rate of the resin composition peaks. In cases when the resin composition has two weight loss rate peaks, TCMP is the lower-temperature-peak temperature.)
C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
C08K 5/521 - Esters of phosphoric acids, e.g. of H3PO4
C08L 23/00 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
C08L 101/00 - Compositions of unspecified macromolecular compounds
Provided are a coolant and a cooling device capable of reducing bad effects on human bodies. A cooling device 1A for cooling an engine mounted in a vehicle wherein a coolant is used for cooling an engine 2, said coolant containing no ethylene glycol and comprising, as a main component, a polyol ester which is a lubricating oil having a freezing point of -70°C or lower. The cooling device 1A, which comprises a coolant flow channel 3 for circulating the coolant and a pump 4 for allowing the coolant in the coolant flow channel 3 to flow, is characterized in that the pump 4 is a gear pump which allows the coolant to flow by gears.
C10N 30/00 - Specified physical or chemical property which is improved by the additive characterising the lubricating composition, e.g. multifunctional additives
Provided is a transformer oil that has high environmental compatibility and is expected to be further improved in transformer cooling properties. A transformer oil prepared by mixing a vegetable oil with a silicone oil and contains no mineral oil, said transformer oil being characterized in that the ratio of the volume of the vegetable oil to the volume of the silicone oil is 3:7 to 7:3 and magnetic particles (e.g., temperature-sensitive magnetic particles) are dispersed in the transformer oil.
C10M 107/50 - Lubricating compositions characterised by the base-material being a macromolecular compound containing silicon
H01B 3/20 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances liquids, e.g. oils
H01B 3/46 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances plasticsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances resinsInsulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes silicones
C10N 30/00 - Specified physical or chemical property which is improved by the additive characterising the lubricating composition, e.g. multifunctional additives
C10N 40/16 - Electric or magnetic purposes dielectricInsulating oil
98.
MULTI-SCREW KNEADER AND METHOD FOR PRODUCING NANO-COMPOSITE USING SAID MULTI-SCREW KNEADER, AND DISK-SHAPED SEGMENT USED FOR SAID KNEADER AND SAID METHOD
Provided are: a multi-screw kneader in which extension and flow actions which act before and after small holes in a disk-shaped segment having the small holes can be sufficiently exhibited; a method for producing a nano-composite using the multi-screw kneader; and a disk-shaped segment used for said kneader and said method. This multi-screw kneader is provided with a plurality of kneading screws and a disk-shaped segment in a barrel. The disk-shaped segment partitions the inside of the barrel at a downstream side from a kneading material feeding part, and is provided with: a plurality of shaft penetrating sections through which the rotation shaft of each kneading screw pass in a rotatable manner; and a plurality of small holes which are perforated around the shaft penetrating sections and serve as flow passages for the kneading material. This method for producing a nano-composite includes a step of feeding nanoparticles as a resin additive by using the multi-screw kneader. This disk-shaped segment is provided with the shaft penetrating sections and the plurality of small holes.
B29B 7/48 - MixingKneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
99.
Liquid-crystal varifocal lens and focal length control method
A liquid-crystal varifocal lens includes a liquid crystal lens, and an ultrasonic transducer for generating an ultrasonic wave with a frequency that matches a resonant frequency of the liquid crystal lens. The ultrasonic transducer generates flexural oscillation in the liquid crystal lens such that the flexural oscillation has a vibration intensity decreasing continuously from the center to the circumference of a liquid crystal layer, whereby the thickness of the liquid crystal layer is changed, with the result that the orientation of the liquid crystal molecules is changed.
G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection
G02F 1/11 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on acousto-optical elements, e.g. using variable diffraction by sound or like mechanical waves
B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
G02F 1/133 - Constructional arrangementsOperation of liquid crystal cellsCircuit arrangements
G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors
An ACAT inhibitor can be more efficiently delivered into the brain by means of a nasally administered medical composition containing: a monohydrochloride of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazine-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide; and an organic acid.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
patents
